As Lyndra Therapeutics works to advance long-acting oral drugs for a range of diseases, the Massachusetts-based biotech is tapping contracting juggernaut Thermo Fisher Scientific to help meet its research and manufacturing needs.
Under a new collaboration unveiled Wednesday, Lyndra is bringing Thermo Fisher on board to tackle commercial manufacturing and global clinical research services. The team-up will specifically enlist Thermo Fisher’s end-to-end manufacturing facility in Cincinnati for commercial-scale production services, according to a press release.
Lyndra says its platform is designed to allow for stable and sustained drug delivery for a week or longer using a single oral dose.
The research and manufacturing partnership, which was announced on the sidelines of the 2025 J.P. Morgan Healthcare Conference in San Francisco, comes after Lyndra reported a phase 3 efficacy win for its long-acting risperidone candidate in adult patients with schizophrenia and schizoaffective disorder last January.
At the time, Lyndra said its candidate—a novel version of the long-established schizophrenia med Risperdal—delivered comparable efficacy to daily Risperdal during an interim analysis.
Given the favorable results, Lyndra elected to stop the study early. The biotech’s long-acting risperidone candidate is slated to enter a phase 3 safety trial in the first half of 2025.